Loading...

NEXTGEN GENECORE PARADIGM PANEL BY NGS, PERIPHERAL BLOOD

image not found

 NABL Cap Accredited 
The NextGen GeneCore Paradigm Panel at Metropolis Healthcare is a broad-spectrum liquid biopsy test designed to analyze multiple cancer-associated genes using a simple peripheral blood sample. This panel detects clinically relevant mutations that influence cancer diagnosis, prognosis, treatment selection, and therapy resistance. With high-sensitivity Next Generation Sequencing, Metropolis Healthcare ensures accurate detection of circulating tumor DNA, making this test valuable when tissue biopsy is not possible or when ongoing molecular monitoring is needed. It supports personalized oncology by providing actionable genomic insights for precision treatment planning

  • 17 Crores+ Samples Processed
  • World Class Technology Labs
  • 25+ Years of Trust & Experience
  • Free Home Collection

Price: Rs. 180,000.00

Sample Type: Blood

Fasting Not Required


Notes:N8281

Frequently Asked Questions (FAQ's):

 What does the GeneCore Paradigm Panel include?

It covers a wide range of cancer-related genes to identify actionable mutations, resistance markers, and clinically significant variants.

Why is this test important?
It helps guide personalized cancer treatment, monitor tumor evolution, and detect emerging genetic changes using a non-invasive method.

Who should take this test?
Patients with solid tumors, those unable to undergo tissue biopsy, or individuals requiring serial molecular monitoring may benefit from this panel.

How does Metropolis Healthcare perform this test?
Metropolis Healthcare uses high-depth NGS technology to analyze circulating tumor DNA (ctDNA) with exceptional accuracy.

What type of sample is required?
A peripheral blood sample collected in specialized NGS-compatible tubes is used for the analysis.

Is any special preparation needed?
No fasting or specific preparation is required before blood collection.

How fast are the results available?
Metropolis Healthcare typically provides comprehensive genomic reports within a clinically appropriate timeframe.

Can this test guide treatment decisions?
Yes, the detected mutations can help oncologists select targeted therapies, immunotherapy options, and personalized treatment strategies

OUR corporates PARTNER

Feedback

Patient's Testimonials

Trusted by Thousands

OUR Accreditations

OUR Lab